Lenvatinib Plus Pembrolizumab Generates Responses But No OS Benefit in HNSCC
Although frontline treatment with lenvatinib plus pembrolizumab improved ORR and PFS, it did not improve OS when compared with placebo in patients with head and neck squamous cell carcinoma.
SABR Yields ’Exceptional‘ Outcomes in Older Patients With Inoperable Renal Cell Carcinoma
Older patients with kidney cancer experienced “exceptional” disease control with stereotactic ablative radiotherapy—which is noninvasive and occurs in the outpatient setting.
Navigators Prove Crucial in Improving Genomic Testing Rates Among Black Patients With Prostate Cancer
Clinical navigators helped increase the rate of genomic testing referrals among Black patients with prostate cancer—a group that faces significant health disparities in the care system.
HPV ctDNA Testing Successfully Predicts Recurrence in Cervical Cancer
Liquid biopsies helped determine which patients with cervical cancer were at a high risk of recurrence following chemoradiation.
Long-Term Safety and Efficacy Is Reported With Partial-Breast Radiotherapy in Early-Stage Breast Cancer
Reduced-dose or partial-breast radiotherapy showed comparable safety and efficacy outcomes compared with whole-breast radiotherapy.
Vaginal Dilation and Sexual Activity Linked to Lower Sexual Dysfunction Following Cervical Cancer Treatment
Cervical cancer survivors who regularly engage in sex or use vaginal dilators report lower levels of vaginal shortening.
New Approach to Palliative Radiation Plans Reduces the Amount of Time Patients Spend in Treatment Centers
Using diagnostic CT scans to create palliation plans may save time and improve the patient experience.
Following Reconstruction, Patients With Early Breast Cancer May Safely Opt For a Shorter Course of Radiation Therapy
Patients with early breast cancer may safely choose a shorter course of radiation therapy following reconstruction.
Nurses Lead Toxicity Monitoring in Indolent Lymphoma Care
Osimertinib/Chemo Boosts Survival in Frontline EGFR+ NSCLC
Lutetium Lu 177 Dotatate Brings Partial Response in Metastatic BP-NETs
Safety Management With Amivantamab Plus Lazertinib in NSCLC